Edoxaban
- Generic Name
- Edoxaban
- Brand Names
- Lixiana, Savaysa, Roteas
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30ClN7O4S
- CAS Number
- 480449-70-5
- Unique Ingredient Identifier
- NDU3J18APO
- Background
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic em...
- Indication
Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the tr...
- Associated Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism
- Associated Therapies
- -
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-05-06
- Target Recruit Count
- 1506
- Registration Number
- NCT02866175
- Locations
- 🇺🇦
Kharkiv City Clinical Hospital #8, Kharkiv, Ukraine
🇬🇧Altnagelvin Area Hospital, Londonderry, United Kingdom
🇬🇧Golden Jubilee Hospital, Clydebank, United Kingdom
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
- Conditions
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 290
- Registration Number
- NCT02798471
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇭🇷Clinical Hospital Centre Rijeka, Rijeka, Croatia
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 811
- Registration Number
- NCT02744092
- Locations
- 🇺🇸
Washington Hospital, Fremont, California, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Saint Joseph's Medical Center, Stockton, California, United States
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Atrial Fibrillation Network
- Target Recruit Count
- 2608
- Registration Number
- NCT02618577
- Locations
- 🇩🇪
Several Sites, Multiple Locations, Germany
🇬🇧Several, Multiple Locations, United Kingdom
EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Electrophysiology Research Foundation
- Target Recruit Count
- 5
- Registration Number
- NCT02561897
- Locations
- 🇺🇸
Electrophysiology Research Foundation, Warren, New Jersey, United States
Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography
- Conditions
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- LifeBridge Health
- Target Recruit Count
- 40
- Registration Number
- NCT02448901
- Locations
- 🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States
Edoxaban for TIA and Acute Minor Stroke
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 3700
- Registration Number
- NCT02221102
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China
Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2020-05-21
- Target Recruit Count
- 65
- Registration Number
- NCT02207257
- Locations
- 🇺🇸
Quintiles, Overland Park, Kansas, United States
Cancer Venous Thromboembolism (VTE)
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1046
- Registration Number
- NCT02073682
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2199
- Registration Number
- NCT02072434
- Locations
- 🇪🇸
First site in, Madrid, Spain
🇪🇸Third site in, Madrid, Spain
🇩🇪Bad Friedrichshall, Heilbronn, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.